Shots: 

• Emergent will acquire Adapt with its leading product Narcan- approved by the FDA and Health Canada for the treatment of known or suspected opioid overdose       
•  Under the agreement- Adapt will receive total up to $735M- including $635M upfront ($575M cash + $60M Emergent common stock)- additionally $100M sales milestone payments on till 2022
• The acquisition is expected to bring increment in revenue $200 to 220M and EBITDA in 2019- expected acquisition completion in Q4’18

/ article | Ref: Emergent BioSolutions  | Image: Emergency services